Longeveron LGVN 深 沪
等待开盘 08-15 09:30:00 美东时间
0.7552
-0.105
-12.19%
华盛通- 最 高0.86
- 今 开0.86
- 成交量 196.80万股
- 最 低 0.74
- 昨 收 0.86
- 总市值 1133.50万
- 52周最高 2.63
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 0.633
- 委 比 53.49%
- 总股本 1500.93万
- 历史最高 450.00
- 量 比 0.31
- 振 幅 13.95%
- 历史最低 0.633
- 每 手 1
- 风险率 0.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Longeveron shares are trading lower after the company reported worse-than-expected Q2 sales results.
Longeveron shares are trading lower after the company reported worse-than-expec...
今天 01:28
Longeveron Q2 EPS $(0.33) Beats $(0.35) Estimate, Sales $316.000K Miss $414.650K Estimate
Longeveron (NASDAQ:LGVN) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.35) by 5.71 percent. This is a 81.97 percent increase over losses of $(1.83) per share from the
08-14 04:40
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
Preview: Longeveron's Earnings
Longeveron (NASDAQ:LGVN) is set to give its latest quarterly earnings report on...
08-13 02:01
Longeveron Closes $5 Million Public Stock Offering
Longeveron ( ($LGVN) ) has issued an announcement. On August 8, 2025, Longevero...
08-12 04:52
Longeveron Announces Closing Of Up To $17.5 Million Public Offering
Longeveron Inc. (NASDAQ: LGVN) has completed a public offering, raising approximately $5.0 million upfront, with potential additional $12.5 million from short-term warrants. The funds will support clinical development of laromestrocel for treating conditions like HLHS, Alzheimer's disease, and pediatric DCM, and advancing regulatory approvals.
08-11 20:15
Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025
Longeveron Inc. (NASDAQ: LGVN) announced it will report second quarter 2025 financial results and provide a business update on August 13, 2025, after U.S. markets close. A conference call and webcast will be held at 4:30 p.m. ET on the same day. The company specializes in regenerative medicines, with its lead product laromestrocel targeting rare pediatric and aging-related conditions.
08-05 13:15
Longeveron Licenses Issued US Patent For Stem Cell Technology From University Of Miami
Longeveron has licensed issued US Patent 12,168,028 B2, entitled "Methods for obtaining cardiomyogenic precursor cells" from the University of MiamiNew patent protects a method to derive GHRH-Receptor+ cardiomyogenic
07-21 21:16
Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease
Longeveron Inc. licensed a new U.S. patent (12,168,028 B2) from the University of Miami, protecting a method to derive GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells. This technology enables safer differentiation into human cardiac muscle cells and avoids complications like malignant ventricular arrhythmias. Joshua Hare, MD, Co-founder, Chief Science Officer, and Chairman, noted this innovation could expand their stem cell therap...
07-21 13:15
Longeveron Announces FDA Approval Of IND Application For Stem Cell Therapy Laromestrocel As Potential Treatment For Pediatric Dilated Cardiomyopathy
Accepted IND application allows for development program to move directly to a Phase 2 pivotal registration clinical trialPhase 2 clinical trial initiation anticipated in first half of 2026Pediatric cardiomyopathies
07-08 21:17
